Alpha 2.0
Login Register
» Articles » PMID: 25686614

Paraneoplastic Cerebellar Degeneration with Anti-CV2/CRMP5 Antibodies and Prostate Adenocarcinoma

Overview
Journal Neurol Sci
Specialty Neurology
Date 2015 Feb 18
PMID 25686614
Citations 7
Authors
A Aliprandi
A Terruzzi
A Rigamonti
E Bazzigaluppi
L Tremolizzo
C Ferrarese
A Salmaggi
Affiliations
Soon will be listed here.
Citing Articles

An overview on CV2/CRMP5 antibody-associated paraneoplastic neurological syndromes.

Wang S, Hou H, Tang Y, Zhang S, Wang G, Guo Z Neural Regen Res. 2023; 18(11):2357-2364.

PMID: 37282453 PMC: 10360094. DOI: 10.4103/1673-5374.371400.

Paraneoplastic Cerebellar Degeneration with Anti-CV2/CRMP5 Antibodies in Ovarian Cancer: Case Report and Review of the Literature.

Juarez-Vignon Whaley J, Carrera-Muinos A, Hernandez-Gutierrez K, Rodriguez-Cid J, Otero-Cerdeira M, Garcia-Montes V Case Rep Oncol. 2022; 14(3):1799-1805.

PMID: 35111012 PMC: 8787574. DOI: 10.1159/000519969.

Anti-CV2/CRMP5 antibody-positive paraneoplastic neurological syndromes with chronic intestinal pseudo-obstruction in a small-cell lung cancer patient: a case report and literature review.

Yan J, Chen Z, Liang Y, Yang H, Cao L, Zhou Y J Int Med Res. 2020; 48(12):300060520974466.

PMID: 33305627 PMC: 7734506. DOI: 10.1177/0300060520974466.

Anti-SOX1 Antibodies in Paraneoplastic Neurological Syndrome.

Sun X, Tan J, Sun H, Liu Y, Guan W, Jia J J Clin Neurol. 2020; 16(4):530-546.

PMID: 33029958 PMC: 7541980. DOI: 10.3988/jcn.2020.16.4.530.

Paraneoplastic basal ganglia encephalitis associated with anti-CV2/CRMP-5 and anti-Yo antibodies in a patient with non-small-cell lung cancer.

Vakrakou A, Constantinides V, Velonakis G, Tzartos J, Stefanis L, Kapaki E Neurol Sci. 2020; 41(9):2649-2651.

PMID: 32307664 DOI: 10.1007/s10072-020-04399-1.

References
1.
Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G . Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol. 2010; 67(3):330-5. DOI: 10.1001/archneurol.2009.341. View
2.
Honnorat J, Cartalat-Carel S, Ricard D, Camdessanche J, Carpentier A, Rogemond V . Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry. 2008; 80(4):412-6. PMC: 2664637. DOI: 10.1136/jnnp.2007.138016. View
3.
Saloustros E, Zaganas I, Mavridis M, Vamvakas L, Plaitakis A, Georgoulias V . Anti-CV2 associated cerebellar degeneration after complete response to chemoradiation of head and neck carcinoma. J Neurooncol. 2009; 97(2):291-4. DOI: 10.1007/s11060-009-0022-2. View
4.
Antoine J, Honnorat J, Vocanson C, Koenig F, Aguera M, Belin M . Posterior uveitis, paraneoplastic encephalomyelitis and auto-antibodies reacting with developmental protein of brain and retina. J Neurol Sci. 1993; 117(1-2):215-23. DOI: 10.1016/0022-510x(93)90176-y. View
5.
Stich O, Rauer S . Antigen-specific oligoclonal bands in cerebrospinal fluid and serum from patients with anti-amphiphysin- and anti-CV2/CRMP5 associated paraneoplastic neurological syndromes. Eur J Neurol. 2007; 14(6):650-3. DOI: 10.1111/j.1468-1331.2007.01802.x. View